Quantcast
Published On: Mon, Apr 14th, 2014

Cellceutix’s CTIX1278 shows promising early results in treating antibiotic resistant Klebsiella pneumoniae

PRESS RELEASE

Cellceutix Corporation, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to report favorable results in a recently completed preclinical study evaluating its novel antibiotic compounds against specific strains of multi-drug resistant Klebsiella pneumoniae. The research, which is government funded through existing grants to research institutions, is being conducted at a major university in Texas.

 

Klebsiella pneumoniae Image/CDC

Klebsiella pneumoniae
Image/CDC

In a thigh burden study of a multi-drug resistant strain of Klebsiella pneumoniae in a mouse model, Cellceutix’s defensin mimetic compound CTIX1278, was efficacious as compared to a carbapenem antibiotic that is widely used as a last line of defense against drug-resistant, Gram-negative bacteria, including Klebsiella pneumoniae. A second study is now being conducted at multiple dosing levels with various infusion parameters with the goal of increasing efficacy and further defining a treatment protocol for the compound.

“This is highly encouraging early data of CTIX1278 as it is the first example of efficacy in vivo with one of our defensin mimetic compounds versus Klebsiella pneumoniae,” comments Dr. Krishna Menon, Chief Scientific Officer at Cellceutix. “A Gram-negative bacteria, Klebsiella pneumoniae is one of the world’s most dangerous superbugs; strains of this bacteria are rapidly emerging that are resistant to virtually every antibiotic available today. The world is staring down the barrel at a growing number of bacteria that can’t be killed by available drugs and the last line of defense is wearing thin. We are very pleased with this latest study providing another piece of evidence that our defensin mimetics have the potential to introduce the first new class of antibiotic drugs in more than two decades to combat the growing problem of antibiotic resistance.”

As it conducts the second study for Klebsiella pneumoniae, the university is awaiting additional materials to begin in vivo research in models of superficial and deep tissue wounds. In these studies, infecting organisms include Gram-negative multi-drug resistant Pseudomonas aeruginosa and Acinetobacter baumannii. This research is also being funded through existing government grants.

On the DISPATCH: Headlines  Local  Opinion

Subscribe to Weekly Newsletter

* indicates required
/ ( mm / dd ) [ALL INFO CONFIDENTIAL]

About the Author

- The generic Dispatch designation, used primarily for press releases or syndicated content, but may be used for guest author requesting a generic nomenclature

Tags

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

Sign up for our Weekly Newsletter



Categories

Archives

At the Movies

Pin It